4/A//SEC Filing
Thakkar Roopal 4/A
Accession 0001415889-25-003337
CIK 0001551152other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 4:00 PM ET
Size
14.7 KB
Accession
0001415889-25-003337
Insider Transaction Report
Form 4/AAmended
AbbVie Inc.ABBV
Thakkar Roopal
EVP, R&D and CSO
Transactions
- Award
Common Stock, $0.01 par value
2024-02-15+5,900→ 36,125 total - Award
Common Stock, $0.01 par value
2024-02-15+1,572→ 37,697 total - Award
Option (Right to buy)
2024-02-15+13,868→ 13,868 totalExercise: $175.28From: 2025-02-15Exp: 2034-02-14→ Common Stock (13,868 underlying) - Award
Common Stock, $0.01 par value
2024-02-15+1,476→ 39,173 total - Award
Common Stock, $0.01 par value
2024-02-15+2,140→ 41,313 total
Footnotes (6)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027.
- [F6]Due to an administrative error the exercise price for options awarded February 15, 2024 was previously reported as $0 but the correct value of $175.28 is reflected in this amendment.
Documents
Issuer
AbbVie Inc.
CIK 0001551152
Entity typeother
Related Parties
1- filerCIK 0002004979
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 4:00 PM ET
- Size
- 14.7 KB